Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leukaemia group backs Curis' dual Pi3K/HDAC inhibitor with $4 million

This article was originally published in Scrip

Executive Summary

Curis will be getting a boost of up to $4 million in funding from the Leukemia & Lymphoma Society (LLS), which has agreed to support 50% of the direct development costs for CUDC-907, a oral small molecule dual Pi3K and HDAC inhibitor under investigation as a treatment for patients with B-cell lymphoma and multiple myeloma.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel